FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:961-962 March 27, 1997 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Sacks, F. M.

To the Editor: The long-awaited results of the Cholesterol and Recurrent Events (CARE) trial (Oct. 3 issue)¹ confirm and extend the results of the virtually unbroken string of coronary disease prevention trials demonstrating the efficacy of substantial reductions in low-density lipoprotein (LDL) cholesterol in preventing coronary heart disease (notably with respect to secondary prevention). Since the reduction in risk in this study was proportional to base-line levels of LDL cholesterol, with benefit being confined to patients with higher pretreatment LDL levels (who were therefore at higher risk), even if the levels fell within the normal range, these findings are both . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.